A phase I trial of Amplimexon (Imexon Inj) administered daily for 5 days every 3 weeks to patients with metastatic cancer or disseminated malignancy
Phase of Trial: Phase I
Latest Information Update: 13 Mar 2008
At a glance
- Drugs Imexon (Primary)
- Indications Cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AmpliMed
- 13 Mar 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
- 23 Oct 2006 New trial record.